Tag «Bristol-Myers Squibb»

BMS-986020

It’s only fair to share… BMS-986020 AM-152; BMS-986020; BMS-986202 cas 1257213-50-5 Chemical Formula: C29H26N2O5 Molecular Weight: 482.536 (R)-1-(4′-(3-methyl-4-(((1-phenylethoxy)carbonyl)amino)isoxazol-5-yl)-[1,1′-biphenyl]-4-yl)cyclopropane-1-carboxylic acid Cyclopropanecarboxylic acid, 1-(4′-(3-methyl-4-((((1R)-1-phenylethoxy)carbonyl)amino)-5-isoxazolyl)(1,1′-biphenyl)-4-yl)- 1-(4′-(3-Methyl-4-(((((R)-1-phenylethyl)oxy)carbonyl)amino)isoxazol-5-yl)biphenyl-4-yl)cyclopropanecarboxylic acid UNII: 38CTP01B4L For treatment for pulmonary fibrosis, phase 2, The lysophosphatidic acid receptor, LPA1, has been implicated as a therapeutic target for fibrotic disorders Lysophospholipids (LPs), including lysophosphatidic acid (LPA), sphingosine 1-phospate (S1P), …

BMS 986205

It’s only fair to share… BMS 986205 (2R)-N-(4-Chlorophenyl)-2-[cis-4-(6-fluoro-4-quinolinyl)cyclohexyl]propanamide Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-α-methyl-, cis- Cyclohexaneacetamide, N-(4-chlorophenyl)-4-(6-fluoro-4-quinolinyl)-α-methyl-, cis-(αR)- (i?)-N-(4-chlorophenyl)-2- c 5-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide CAS: 1923833-60-6 Phase 1 cancer BMS-986205, ONO-7701,  F- 001287 Molecular Formula C24H24ClFN2O Average mass 410.912 Da Originator Bristol-Myers Squibb Class Antineoplastics 01 Feb 2016 Phase-I/II clinical trials in Cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Canada (PO) (NCT02658890) 31 Jan 2016 Preclinical …

BMS-741672

It’s only fair to share… BMS-741672 N-((1R,2S,5R)-5-(Isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide BMS-741672 N-((lR,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6- (trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-l-yl)cyclohexyl)acetamide N-((1R,2S,5R)-5-(isopropyl(methyl)amino)-2-((S)-2-oxo-3-(6-(trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide; C25 H33 F3 N6 O2, 506.56 Acetamide, N-[(1R,2S,5R)-5-[methyl(1-methylethyl)amino]-2-[(3S)-2-oxo-3-[[6-(trifluoromethyl)-4-quinazolinyl]amino]-1-pyrrolidinyl]cyclohexyl]- CAS 1004757-96-3 PHASE 2, , Treatment of Type 2 Diabetes, Agents for Neuropathic Pain Chemokine CCR2 (MCP-1 Receptor) Antagonists Molecular Formula: C25H33F3N6O2 Molecular Weight: 506.574 g/mol Michael G. Yang, Robert J. Cherney Original Assignee Bristol-Myers Squibb Company Michael G. Yang, …

BMS 906024

It’s only fair to share… BMS 906024 cas 1401066-79-2 MF C26H26F6N4O3 MW 556.500 (2R,3S)-N-[(3S)-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bis(3,3,3-trifluoropropyl)succinamide Butanediamide, N1-((3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluorophenyl)-, (2R,3S)- (2R,35)-N-((35)-l-Methyl-2-oxo-5-phenyl-2,3-dihydro-lH-l,4-benzodiazepin-3-yl)-3- (2,2,2-trifluoroethyl)-2-(3,3,3-trifluoropropyl)succinamide Claude Quesnelle, Soong-Hoon Kim, Francis Lee, Ashvinikumar Gavai Applicant Bristol-Myers Squibb Company Ashvinikumar Gavai   Claude Quesnelle Senior Research Investigator/Chemist at Bristol-Myers Squibb RICHARD LEE BMS-906024 is a novel, potent Notch receptor inhibitor . Cancers have a tendency …